
Investors
Corporate Overview
NewcelX Ltd. (Nasdaq: NCEL) is advancing NCEL-101, a stem cell-derived islet replacement therapy designed to restore functional insulin production, toward a potential functional cure for type 1 diabetes.
Contact us for investor relations at: [email protected]

